A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Heart Failure
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 316 participants.
Also called NCT02012075
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 316 participants
- Registry
-
NCT02012075
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- Not reported
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT02012075. Randomized; double masking; primary purpose treatment. Start 2013-12 (registry gives no type); primary completion 2015-02 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Heart Failure
- Condition
- Heart Failure
- Intervention (Drug)
- Extended-Release Carvedilol Sulfate
- Intervention (Drug)
- Sustained-release Metoprolol Succinate
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Record details
- Record id
cardio:ct-nct02012075- Content hash
1cdb431ba0e67faeeab55c46eac70587535eae00d6e185cf59feaa580651f517